Global Gastric Antral Vascular Ectasia (GAVE) Treatment Market, By Treatment (Surgery, Medical Therapy, Endoscopy), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies and Others) - Industry Trends and Forecast to 2030.
Gastric Antral Ectasia (GAVE) Treatment Market Analysis and Size
The global gastric antral vascular ectasia (GAVE) treatment market is expected to witness significant growth during the forecast period. Risk factors that can cause GAVE are proliferation of neuroendocrine cells, hypergastrinemia, asoactive intestinal polypeptide, changes in the level of prostaglandin E2 hormone, 5-hydroxytryptamine are some of the major risk factors that can boost the gastric antral vascular ectasia (GAVE) treatment market growth. Major outbreak of the COVID-19 pandemic imposed stringent lockdown regulations worldwide, causing interruptions in import and export activities of global gastric antral ectasia (GAVE) treatment market.
Data Bridge Market Research analyses that the gastric antral ectasia (GAVE) treatment market which is expected to undergo a CAGR of 3.5% during the forecast period of 2023 to 2030. “Surgery” dominates the treatment segment of the gastric antral ectasia (GAVE) treatment market owing to the increasing prevalence of gastrointestinal disorders among the population. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Gastric Antral Ectasia (GAVE) Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Treatment (Surgery, Medical Therapy, Endoscopy), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
|
|
Market Opportunities
|
|
Market Definition
Gastric antral vascular ectasia (GAVE), also known as watermelon stomach, is a rare disease related to gastrointestinal bleeding and iron deficiency anemia. It is typically characterized by several endoscopic appearances of roughly formed parallel folds and the blood vessels which are dilated are departing from the pylorus and are uniting in the gastric antrum. The primary symptoms include blood loss, one of the foremost concerns for patients suffering from this disease. Other symptoms are blood in stool or during vomiting, internal bleeding can be shown if the blood test is performed on a regular basis. This disease prevalence is rising and essential diagnostic procedures and treatments will boost the growth of the market.
Gastric Antral Ectasia (GAVE) Treatment Market Dynamics
Drivers
- Increasing Prevalence of Gastrointestinal Disorders
Other gastrointestinal conditions like cirrhosis, portal hypertension, and autoimmune illnesses frequently coexist with gastric antral ectasia. The increased incidence of gastric antral ectasia is a result of the rising prevalence of several related disorders. The rising number of patients with these comorbidities has a beneficial impact on the market for gastric antral ectasia.
- Increasing Geriatric Population
Older people are more likely to have gastric antral ectasia. An important market driver is the ageing population, particularly in wealthy nations. The prevalence of stomach antral ectasia rises with an ageing population, increasing the need for diagnostic and treatment approaches.
- Rising Awareness Regarding the Disease
Gastric antral ectasia has gradually been more widely known among patients, healthcare providers, and the general public throughout time. Early identification and effective treatment have resulted from a better understanding of the ailment and its symptoms. Through the expansion of the patient base and the facilitation of appropriate treatment, increased disease awareness promotes market expansion.
Opportunities
- Increasing Healthcare Expenditure
Global healthcare spending is increasing, especially in developing nations, which is boosting the gastric antral ectasia market. Better infrastructure, easier access to healthcare services, and more cutting-edge treatment alternatives are made possible by more healthcare spending. This pattern offers a supportive environment for market growth and the uptake of novel treatments.
- Growing demand of Personalised Medicine
The market for stomach antral ectasia could benefit from the idea of personalised medicine, which adapts therapies to specific patients depending on their particular characteristics. The development of more individualised and targeted treatment plans may be made possible by improvements in genetic testing, biomarker identification, and precision medicine methods. Adopting personalised medicine can improve treatment results, maximise resource use, and provide new business opportunities.
- Rising Collaborations among the Key Market Players
Collaboration between medical professionals, pharmaceutical firms, and patient advocacy organisations offers a chance to advance the stomach antral ectasia market. Stakeholders can hasten the development of innovative medicines, enhance patient care, and address the unmet needs of the patient population by forging collaborations, exchanging knowledge, and pooling resources.
Restrains
- Limited Research and Trial Activities
There are few research studies and clinical trials aimed at creating new treatments for stomach antral ectasia because of its rarity. The lack of sufficient research information and evidence-based understanding of the illness impedes the creation of efficient therapeutic choices and impedes the growth of the market.
- High Cost of Treatment
The expense of diagnosing and treating stomach antral ectasia might be significant. The illness is uncommon, though, therefore reimbursement procedures and healthcare payer coverage may not be well-established. This may make it more difficult for patients to afford treatment and make it more difficult for businesses to set competitive prices for their goods.
Challenges
- Limited Treatment Options
As previously stated, there is presently no known cure for stomach antral ectasia, and available therapies mainly aim to control symptoms and stop bleeding. The market's potential for expansion is constrained by the absence of specialised and efficient treatment options. Patients might be forced to use palliative care, which would result in a poor quality of life.
- Limited Reimbursement Policies
The price of diagnostic exams, endoscopic treatments, and other stomach antral ectasia therapy techniques might be high. The lack of established or thorough payment rules, however, can make it difficult for patients to afford the essential care. The restricted options for reimbursement and coverage may significantly impede market expansion.
This global gastric antral vascular ectasia (GAVE) treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global gastric antral vascular ectasia (GAVE) treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Gastric Antral Ectasia (GAVE) Treatment Market Scope
The global gastric antral vascular ectasia (GAVE) treatment market is segmented on the basis of treatment, end-users, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Treatment
- Surgery
- Medical Therapy
- Endoscopy
End-Users
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Gastric Antral Ectasia (GAVE) Treatment Market Regional Analysis/Insights
The global gastric antral vascular ectasia (GAVE) treatment market is analyzed and market size insights and trends are provided by treatment, end-users, distribution channel as referenced above.
The major countries covered in the global gastric antral vascular ectasia (GAVE) treatment market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is considered to have the highest lucrative growth in the forecast period due to the rising investments by hospitals to purchase new endoscopic equipment and growing research activities to enhance endoscopy.
Asia-Pacific is dominating the market due to the presence of key generic pharmaceuticals companies in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Gastric Antral Ectasia (GAVE) Treatment Market Share Analysis
The global gastric antral vascular ectasia (GAVE) treatment market market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global gastric antral vascular ectasia (GAVE) treatment market.
Some of the major players operating in the gastric antral vascular ectasia (GAVE) treatment market are:
- Olympus Corporation (Japan)
- Boston Scientific Corporation (U.S.)
- FUJIFILM Corporation (Japan)
- Cook (U.S.)
- Medtronic (U.S.)
- Hoya Corporation (Japan)
- Richard Wolf GmbH (Germany)
- KARL STORZ(Germany)
- Stryker (U.S.)
- Smith+Nephew (U.K.)
SKU-